Aptagen, LLC
Human Plasma Proteins DNA Aptamer AS1411 (ID# 8486)
DNA
Human Plasma Protein
Protein
34.25 nM (reported value)
Binding buffer was composed of DPBS supplemented with 5mM MgCl2, 4.5 g/L glucose (Sangon Biotech), and 1 mg/mL BSA and yeast tRNA (0.1mg/mL, Thermo Fisher Scientific).
37°C
NA If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.
N/A
An overview of the physiological factors that adversely affect the in vivo targeting ability of aptamers using Microscale thermophoresis and flow cytometry analysis to investigate the competitive binding between FN1 and NCL AS1411 aptamer’s targeting ability in vivo.
In order to maintain the targeting function of the AS1411 aptamer, further physiological modifications were optimized leading to improved tumor-targeting effects between the AS1411aptamer and the FN1 protein.
,
5'-dGpdGpdTpdGpdGpdTpdGpdGpdTpdGpdGpdTpdTpdGpdTpdGpdGpdTpdGpdGpdTpdGpdGpdTpdGpdGp-3'
26
8272.3
N/A
Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.
Jia Liu, Zhiqiang Ren, Yang Sun, Liujun Xu, Dali Wei, Weihong Tan, and Ding Ding ACS Nano 2023 17 (23), 24329-24342 DOI: 10.1021/acsnano.3c10238
Have your aptamer oligo synthesized ORDER
We are always looking for ways to improve. Please tell us what you think.